<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="2f881a90-dfd9-314d-e063-6294a90a6f9a"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use PYLARIFY 
 <sup>®</sup>safely and effectively. See full prescribing information for PYLARIFY.
 <br/>
      <br/>
PYLARIFY 
 <sup>®</sup>(piflufolastat F 18) injection, for intravenous use
 <br/>
Initial U.S. Approval: 2021
</title>
   <effectiveTime value="20250304"/>
   <setId root="a00e5cbc-4fd5-4280-82ec-cd3498df4553"/>
   <versionNumber value="10"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="195551247"/>
            <name>Progenics Pharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="528176699"/>
                        <name>Asymchem Life Science (Tianjin) Co., Ltd.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" displayName="api manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="134146484"/>
                        <name>PETNET SOLUTIONS, INC.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="079854636"/>
                        <name>SOFIE Co. dba SOFIE</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="026659644"/>
                        <name>PETNET Solutions, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="079932600"/>
                        <name>N-Molecular Inc. dba SOFIE</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="961682551"/>
                        <name>PETNET Solutions, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="961592982"/>
                        <name>PETNET Solutions, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="101387665"/>
                        <name>PETNET Solutions, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="965557486"/>
                        <name>PETNET Solutions, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="603833208"/>
                        <name>PETNET Solutions, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="032324142"/>
                        <name>SOFIE Co. dba SOFIE</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="928455851"/>
                        <name>SOFIE Co. dba SOFIE</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="128523862"/>
                        <name>PETNET Solutions, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="033883716"/>
                        <name>PETNET Solutions, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="103781071"/>
                        <name>PETNET Solutions, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="079932640"/>
                        <name>N-Molecular, Inc. dba SOFIE</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="118258354"/>
                        <name>SOFIE Co. dba SOFIE</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="961593337"/>
                        <name>PETNET Solutions, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="025600556"/>
                        <name>SOFIE Co. dba SOFIE</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="829109441"/>
                        <name>SOFIE Co. dba SOFIE</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="879283633"/>
                        <name>Precision Nuclear, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="078623800"/>
                        <name>SOFIE Co. dba SOFIE</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="832599976"/>
                        <name>SOFIE Co. dba SOFIE</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="117843428"/>
                        <name>PETNET Solutions, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="123562576"/>
                        <name>PETNET Solutions, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="079932634"/>
                        <name>N-Molecular, Inc. dba SOFIE</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="117608150"/>
                        <name>PharmaLogic Colorado, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="018432646"/>
                        <name>The University of Utah DBA Cyclotron Radiochemistry Lab Huntsman Cancer Institute</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="780624719"/>
                        <name>PETNET Solutions, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="840517945"/>
                        <name>PETNET Solutions, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="622386605"/>
                        <name>Hot Shots Nuclear Medicine, LLC dba Midwest Positron Technology, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="010753961"/>
                        <name>Essential Isotopes, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="796129646"/>
                        <name>PETNET Solutions, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="079262099"/>
                        <name>PETNET Solutions, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="961593386"/>
                        <name>PETNET Solutions, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="078575242"/>
                        <name>PETNET Solutions Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="117749860"/>
                        <name>Wisconsin Medical Radiopharmacy, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="832856756"/>
                        <name>Lantheus MI Radiopharmaceuticals, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="111110727"/>
                        <name>PETNET Solutions, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="154173350"/>
                        <name>PETNET Solutions, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="788930480"/>
                        <name>PETNET Solutions, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="118120165"/>
                        <name>PETNET Solutions, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="961597221"/>
                        <name>PETNET Solutions, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="961597122"/>
                        <name>PETNET Solutions, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="799246256"/>
                        <name>PETNET Solutions, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="080547824"/>
                        <name>PETNET Solutions, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="798775214"/>
                        <name>PETNET Solutions, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="961597072"/>
                        <name>PETNET Solutions, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="018537881"/>
                        <name>PETNET Solutions, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="004201823"/>
                        <name>PETNET Solutions, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="008017970"/>
                        <name>SOFIE Co. dba SOFIE</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="102326340"/>
                        <name>PETNET Solutions, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="621380547"/>
                        <name>P.E.T.NET Houston, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="798884966"/>
                        <name>PETNET Solutions, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="118410433"/>
                        <name>Pharmalogic New York City LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="118408248"/>
                        <name>Pharmalogic Holdings Corp.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="119024924"/>
                        <name>Pharmalogic Los Angeles, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="961597213"/>
                        <name>PETNET Solutions, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="006320902"/>
                        <name>SOFIE Co. dba SOFIE</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="119319723"/>
                        <name>Pharmalogic Salt Lake City, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="118431835"/>
                        <name>Pharmalogic Austin, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="080871737"/>
                        <name>Jubilant DraxImage Inc., dba Jubilant Radiopharma</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="080871701"/>
                        <name>Jubilant DraxImage Inc., dba Jubilant Radiopharma</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="2f9d80b3-1d8d-bab7-e063-6294a90a140a"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250304"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="71258-022" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>PYLARIFY</name>
                        <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>PIFLUFOLASTAT F-18</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3K9958V90M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="VR5Y7PDT5W" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOTONIC SODIUM CHLORIDE SOLUTION</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mCi" value="80"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="3934EF02T7" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PIFLUFOLASTAT F-18</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="3934EF02T7" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PIFLUFOLASTAT F-18</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="50" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="71258-022-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43210" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, MULTI-DOSE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20210526"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA214793" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20210526"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="2f881a90-dfda-314d-e063-6294a90a6f9a"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>PYLARIFY is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:</paragraph>
                  <list listType="unordered">
                     <item>with suspected metastasis who are candidates for initial definitive therapy.</item>
                     <item>with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.</item>
                  </list>
               </text>
               <effectiveTime value="20230331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>PYLARIFY is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:</paragraph>
                        <list listType="unordered">
                           <item>with suspected metastasis who are candidates for initial definitive therapy.</item>
                           <item>with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. (
  
     <linkHtml href="#S1">1</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="2f881a90-dfdb-314d-e063-6294a90a6f9a"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20230331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Recommended dose is 333 MBq (9 mCi) with an acceptable range of 296 MBq to 370 MBq (8 mCi to 10 mCi), administered as a bolus intravenous injection. (
  
     <linkHtml href="#S2.2">2.2</linkHtml>)
 
    </item>
                           <item>Initiate imaging approximately 60 minutes after PYLARIFY administration. The patient should void immediately prior to initiation of imaging. Image acquisition should start from mid-thigh and proceed to the skull vertex. (
  
     <linkHtml href="#S2.3">2.3</linkHtml>,
  
     <linkHtml href="#S2.4">2.4</linkHtml>)
 
    </item>
                           <item>See full prescribing information for additional preparation, handling, administration, imaging, and radiation dosimetry information. (
  
     <linkHtml href="#S2">2</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="2f881a90-dfdc-314d-e063-6294a90a6f9a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Radiation Safety – Drug Handling</title>
                     <text>
                        <paragraph>PYLARIFY is a radioactive drug. Only authorized persons qualified by training and experience should receive, use, and administer PYLARIFY. Handle PYLARIFY with appropriate safety measures to minimize radiation exposure during administration
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]
 
  </content>. Use waterproof gloves and effective radiation shielding, including syringe shields, when preparing and handling PYLARIFY.

 </paragraph>
                     </text>
                     <effectiveTime value="20230331"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="2f881a90-dfdd-314d-e063-6294a90a6f9a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Recommended Dosage and Administration Instructions</title>
                     <effectiveTime value="20230331"/>
                     <component>
                        <section>
                           <id root="2f881a90-dfde-314d-e063-6294a90a6f9a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Recommended Dose</content>
                              </paragraph>
                              <paragraph>The recommended amount of radioactivity to be administered for PET imaging is 333 MBq (9 mCi) with an acceptable range of 296 MBq to 370 MBq (8 mCi to 10 mCi) administered as a single bolus intravenous injection.</paragraph>
                           </text>
                           <effectiveTime value="20230331"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2f881a90-dfdf-314d-e063-6294a90a6f9a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Preparation and Administration</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>Use aseptic technique and radiation shielding when preparing and administering PYLARIFY.</item>
                                 <item>Visually inspect the radiopharmaceutical solution. Do not use if it contains particulate matter or if it is discolored (PYLARIFY is a clear, colorless solution).</item>
                                 <item>Calculate the necessary volume to administer based on calibration time and required dose. PYLARIFY may be diluted with 0.9% Sodium Chloride Injection, USP.</item>
                                 <item>Assay the dose in a suitable dose calibrator prior to administration.</item>
                              </list>
                           </text>
                           <effectiveTime value="20230331"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2f881a90-dfe0-314d-e063-6294a90a6f9a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Post Administration Instructions</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>Follow the PYLARIFY injection with an intravenous flush of 0.9% Sodium Chloride Injection USP.</item>
                                 <item>Dispose of any unused PYLARIFY in compliance with applicable regulations.</item>
                              </list>
                           </text>
                           <effectiveTime value="20230331"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="2f881a90-dfe1-314d-e063-6294a90a6f9a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Patient Preparation</title>
                     <text>
                        <paragraph>Instruct patients to drink water to ensure adequate hydration prior to administration of PYLARIFY and to continue drinking and voiding frequently for the first few hours following administration to reduce radiation exposure
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20230331"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="2f881a90-dfe2-314d-e063-6294a90a6f9a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Image Acquisition</title>
                     <text>
                        <paragraph>The recommended start time for image acquisition is 60 minutes after PYLARIFY injection. Starting image acquisition more than 90 minutes after injection may adversely impact imaging performance. Patients should void immediately prior to image acquisition. Position the patient supine with arms above the head. Image acquisition should start from mid-thigh and proceed to the skull vertex. Scan duration is 12 minutes to 40 minutes depending on the number of bed positions (typically 6 to 8) and acquisition time per bed position (typically 2 minutes to 5 minutes).</paragraph>
                     </text>
                     <effectiveTime value="20230331"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.5">
                     <id root="2f881a90-dfe3-314d-e063-6294a90a6f9a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Image Display and Interpretation</title>
                     <text>
                        <paragraph>PYLARIFY binds to prostate-specific membrane antigen (PSMA). Based on the intensity of the signals, PET images obtained using PYLARIFY indicate the presence of PSMA in tissues. Lesions should be considered suspicious if uptake is greater than physiologic uptake in that tissue or greater than adjacent background if no physiologic uptake is expected. Tumors that do not express PSMA will not be visualized. Increased uptake in tumors is not specific for prostate cancer [
 
  <content styleCode="italics">see
  
   <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>
                           </content>].

 </paragraph>
                     </text>
                     <effectiveTime value="20230331"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.6">
                     <id root="2f881a90-dfe4-314d-e063-6294a90a6f9a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Radiation Dosimetry</title>
                     <text>
                        <paragraph>Radiation absorbed dose estimates are shown in Table 1 for organs and tissues of adult male patients from intravenous administration of PYLARIFY. The radiation effective dose resulting from administration of 370 MBq (10 mCi) of PYLARIFY to an adult weighing 70 kg is estimated to be 4.3 mSv. The radiation doses for this administered dose to the critical organs, which are the kidneys, liver, and spleen, are 45.5 mGy, 13.7 mGy, and 10 mGy respectively. When PET/CT is performed, exposure to radiation will increase by an amount dependent on the settings used in the CT acquisition.</paragraph>
                        <table width="85%">
                           <caption>Table 1. Estimated Radiation Absorbed Doses in Organs/Tissues in Adults who Received PYLARIFY</caption>
                           <col width="33%" align="left" valign="top"/>
                           <col width="34%" align="center" valign="top"/>
                           <col width="33%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th align="center" styleCode="Lrule Rrule Botrule">Organ/Tissue</th>
                                 <th colspan="2" styleCode="Rrule Botrule">Mean Absorbed dose per Unit Administered Activity 
     <br/>  (mGy/MBq)
    </th>
                              </tr>
                              <tr styleCode="Botrule">
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">Mean</th>
                                 <th styleCode="Rrule">Standard Deviation</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Adrenal glands</td>
                                 <td styleCode="Rrule">0.0131</td>
                                 <td styleCode="Rrule">0.0013</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Brain</td>
                                 <td styleCode="Rrule">0.0021</td>
                                 <td styleCode="Rrule">0.0003</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Breasts</td>
                                 <td styleCode="Rrule">0.0058</td>
                                 <td styleCode="Rrule">0.0007</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Gallbladder wall</td>
                                 <td styleCode="Rrule">0.0141</td>
                                 <td styleCode="Rrule">0.0012</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Lower large intestine wall</td>
                                 <td styleCode="Rrule">0.0073</td>
                                 <td styleCode="Rrule">0.001</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Small intestine</td>
                                 <td styleCode="Rrule">0.0089</td>
                                 <td styleCode="Rrule">0.0009</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Stomach wall</td>
                                 <td styleCode="Rrule">0.0092</td>
                                 <td styleCode="Rrule">0.0008</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Upper large intestine wall</td>
                                 <td styleCode="Rrule">0.0091</td>
                                 <td styleCode="Rrule">0.0009</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Heart wall</td>
                                 <td styleCode="Rrule">0.0171</td>
                                 <td styleCode="Rrule">0.0022</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Kidneys</td>
                                 <td styleCode="Rrule">0.123</td>
                                 <td styleCode="Rrule">0.0434</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Liver</td>
                                 <td styleCode="Rrule">0.037</td>
                                 <td styleCode="Rrule">0.0058</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Lungs</td>
                                 <td styleCode="Rrule">0.0102</td>
                                 <td styleCode="Rrule">0.0016</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Muscle</td>
                                 <td styleCode="Rrule">0.0069</td>
                                 <td styleCode="Rrule">0.0008</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Pancreas</td>
                                 <td styleCode="Rrule">0.0124</td>
                                 <td styleCode="Rrule">0.0011</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Red bone marrow</td>
                                 <td styleCode="Rrule">0.0071</td>
                                 <td styleCode="Rrule">0.0007</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Osteogenic cells</td>
                                 <td styleCode="Rrule">0.0099</td>
                                 <td styleCode="Rrule">0.0012</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Skin</td>
                                 <td styleCode="Rrule">0.0052</td>
                                 <td styleCode="Rrule">0.0006</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Spleen</td>
                                 <td styleCode="Rrule">0.0271</td>
                                 <td styleCode="Rrule">0.0115</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Testes</td>
                                 <td styleCode="Rrule">0.0059</td>
                                 <td styleCode="Rrule">0.0008</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Thymus gland</td>
                                 <td styleCode="Rrule">0.007</td>
                                 <td styleCode="Rrule">0.0008</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Thyroid</td>
                                 <td styleCode="Rrule">0.0062</td>
                                 <td styleCode="Rrule">0.0009</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Urinary bladder wall</td>
                                 <td styleCode="Rrule">0.0072</td>
                                 <td styleCode="Rrule">0.001</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Effective dose</content>
                                 </td>
                                 <td styleCode="Rrule">
                                    <content styleCode="bold">0.0116 (mSv/MBq)</content>
                                 </td>
                                 <td styleCode="Rrule">
                                    <content styleCode="bold">0.0022 (mSv/MBq)</content>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20230331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="2f881a90-dfe5-314d-e063-6294a90a6f9a"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Injection: clear, colorless solution in a multiple-dose vial containing 37 MBq/mL to 2,960 MBq/mL (1 mCi/mL to 80 mCi/mL) of piflufolastat F 18 at calibration date and time.</paragraph>
               </text>
               <effectiveTime value="20230331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection: clear, colorless solution in a multiple-dose vial containing 37 MBq/mL to 2,960 MBq/mL (1 mCi/mL to 80 mCi/mL) of piflufolastat F 18 at calibration date and time. (
 
    <linkHtml href="#S3">3</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="2f881a90-dfe6-314d-e063-6294a90a6f9a"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20230331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None. (
 
    <linkHtml href="#S4">4</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="2f881a90-dfe7-314d-e063-6294a90a6f9a"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20230331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <content styleCode="underline">Risk of Image Misinterpretation</content>: PYLARIFY uptake can be seen in a variety of tumor types as well as in non-malignant processes and normal tissues. Image interpretation errors can occur with PYLARIFY imaging. (
  
     <linkHtml href="#S5.1">5.1</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="underline">Hypersensitivity Reactions</content>: Monitor patients for hypersensitivity reactions, particularly patients with a history of allergy to other drugs and foods. (
  
     <linkHtml href="#S5.2">5.2</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="underline">Radiation Risk</content>: Ensure safe drug handling to protect patients and health care workers from unintentional radiation exposure. (
  
     <linkHtml href="#S5.3">5.3</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="2f881a90-dfe8-314d-e063-6294a90a6f9a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Risk of Image Misinterpretation</title>
                     <text>
                        <paragraph>Imaging interpretation errors can occur with PYLARIFY imaging. A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer. The performance of PYLARIFY for imaging of patients with biochemical evidence of recurrence of prostate cancer seems to be affected by serum PSA levels [
 
  <content styleCode="italics">see
  
   <linkHtml href="#S14">Clinical Studies (14)</linkHtml>
                           </content>]. The performance of PYLARIFY for imaging of metastatic pelvic lymph nodes prior to initial definitive therapy seems to be affected by risk factors such as Gleason score and tumor stage [
 
  <content styleCode="italics">see
  
   <linkHtml href="#S14">Clinical Studies (14)</linkHtml>
                           </content>]. PYLARIFY uptake is not specific for prostate cancer and may occur with other types of cancer as well as non-malignant processes and in normal tissues. Clinical correlation, which may include histopathological evaluation of the suspected prostate cancer site, is recommended.

 </paragraph>
                     </text>
                     <effectiveTime value="20230331"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="2f881a90-dfe9-314d-e063-6294a90a6f9a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>Monitor patients for hypersensitivity reactions, particularly patients with a history of allergy to other drugs and foods. Reactions may not be immediate. Always have trained staff and resuscitation equipment available.</paragraph>
                     </text>
                     <effectiveTime value="20230331"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="2f881a90-dfea-314d-e063-6294a90a6f9a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Radiation Risks</title>
                     <text>
                        <paragraph>Diagnostic radiopharmaceuticals, including PYLARIFY, expose patients to radiation
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.6">Dosage and Administration (2.6)</linkHtml>]
 
  </content>. Radiation exposure is associated with a dose-dependent increased risk of cancer. Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20230331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="2f881a90-dfeb-314d-e063-6294a90a6f9a"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <effectiveTime value="20230331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common reported adverse reactions are headache, dysgeusia, and fatigue. (
 
    <linkHtml href="#S6.1">6.1</linkHtml>)

   </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Progenics Pharmaceuticals, Inc. at 1-800-362-2668 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="2f881a90-dfec-314d-e063-6294a90a6f9a"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The safety of PYLARIFY was evaluated in 593 patients, each receiving one dose of PYLARIFY. The average injected activity was 340 ± 26 MBq (9.2 ± 0.7 mCi).</paragraph>
                        <paragraph>The adverse reactions reported in &gt;0.5% of patients within the studies are shown in Table 2. In addition, a hypersensitivity reaction was reported in one patient (0.2%) with a history of allergic reaction.</paragraph>
                        <table width="85%">
                           <caption>Table 2. Adverse Reactions with a Frequency &gt;0.5% in Patients Who Received PYLARIFY (n = 593)</caption>
                           <col width="30%" align="left" valign="top"/>
                           <col width="70%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule">Adverse Reaction</th>
                                 <th styleCode="Rrule">n (%)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Headache</td>
                                 <td styleCode="Rrule">13 (2%)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Dysgeusia</td>
                                 <td styleCode="Rrule">10 (2%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Fatigue</td>
                                 <td styleCode="Rrule">7 (1%)</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20230331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="2f881a90-dfed-314d-e063-6294a90a6f9a"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20230331"/>
               <component>
                  <section>
                     <id root="2f881a90-dfee-314d-e063-6294a90a6f9a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Androgen deprivation therapy and other therapies targeting the androgen pathway</content>
                        </paragraph>
                        <paragraph>Androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, may result in changes in uptake of PYLARIFY in prostate cancer. The effect of these therapies on performance of PYLARIFY PET has not been established.</paragraph>
                     </text>
                     <effectiveTime value="20230331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="2f881a90-dfef-314d-e063-6294a90a6f9a"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20230331"/>
               <component>
                  <section ID="S8.1">
                     <id root="2f881a90-dff0-314d-e063-6294a90a6f9a"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20230331"/>
                     <component>
                        <section>
                           <id root="2f881a90-dff1-314d-e063-6294a90a6f9a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>PYLARIFY is not indicated for use in females. There is no information on the risk of adverse developmental outcomes in pregnant women or animals with the use of piflufolastat F 18. All radiopharmaceuticals, including PYLARIFY, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose.</paragraph>
                           </text>
                           <effectiveTime value="20230331"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="2f881a90-dff2-314d-e063-6294a90a6f9a"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20230331"/>
                     <component>
                        <section>
                           <id root="2f881a90-dff3-314d-e063-6294a90a6f9a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>PYLARIFY is not indicated for use in females. There is no information on the presence of piflufolastat F 18 in human milk, the effect on the breastfed infant, or the effect on milk production.</paragraph>
                           </text>
                           <effectiveTime value="20230331"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="2f881a90-dff4-314d-e063-6294a90a6f9a"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of PYLARIFY in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20230331"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="2f881a90-dff5-314d-e063-6294a90a6f9a"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Of the 593 patients in completed clinical studies of PYLARIFY, 355 (60%) were ≥65 years old, while 76 (12.8%) were ≥75 years old. The efficacy and safety of PYLARIFY appear similar in adult and geriatric patients with prostate cancer, although the number of patients in the trials was not large enough to allow definitive comparison.</paragraph>
                     </text>
                     <effectiveTime value="20230331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="2f881a90-dff6-314d-e063-6294a90a6f9a"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>In the event of an overdose of PYLARIFY, reduce the radiation absorbed dose to the patient where possible by increasing the elimination of the drug from the body using hydration and frequent bladder voiding. A diuretic might also be considered. If possible, an estimate of the radiation effective dose administered to the patient should be made.</paragraph>
               </text>
               <effectiveTime value="20230331"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="2f881a90-dff7-314d-e063-6294a90a6f9a"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <effectiveTime value="20230331"/>
               <component>
                  <section ID="S11.1">
                     <id root="2f881a90-dff8-314d-e063-6294a90a6f9a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>11.1 Chemical Characteristics</title>
                     <text>
                        <paragraph>PYLARIFY contains fluorine 18 (F 18), radiolabeled prostate-specific membrane antigen inhibitor imaging agent. Chemically piflufolastat F 18 is 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}ureido)-pentanedioic acid. The molecular weight is 441.4 and the structural formula is:</paragraph>
                        <renderMultiMedia referencedObject="MM1"/>
                        <paragraph>The chiral purity of the unlabeled piflufolastat F 18 precursor is greater than 99% (S,S).</paragraph>
                        <paragraph>PYLARIFY is a sterile, non-pyrogenic, clear, colorless solution for intravenous injection. Each milliliter contains 37 to 2,960 MBq (1 to 80 mCi) piflufolastat F 18 with ≤0.01 µg/mCi of piflufolastat at calibration time and date, and ≤ 78.9 mg ethanol in 0.9% sodium chloride injection USP. The pH of the solution is 4.5 to 7.0.</paragraph>
                        <paragraph>PYLARIFY has a radiochemical purity of at least 95% up to 10 hours following end of synthesis, and specific activity of at least 1000 mCi/µmol at the time of administration.</paragraph>
                     </text>
                     <effectiveTime value="20230331"/>
                     <component>
                        <observationMedia ID="MM1">
                           <text>Chemical Structure</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="pylarify-01.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S11.2">
                     <id root="2f881a90-dff9-314d-e063-6294a90a6f9a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>11.2 Physical Characteristics</title>
                     <text>
                        <paragraph>PYLARIFY is radiolabeled with fluorine 18 (F 18), a cyclotron produced radionuclide that decays by positron emission to stable oxygen 18 with a half-life of 109.8 minutes. The principal photons useful for diagnostic imaging are the coincident pair of 511 keV gamma photons, resulting from the interaction of the emitted positron with an electron (Table 3).</paragraph>
                        <table width="85%">
                           <caption>Table 3. Principal Radiation Produced from Decay of Fluorine 18</caption>
                           <col width="33%" align="left" valign="top"/>
                           <col width="34%" align="left" valign="top"/>
                           <col width="33%" align="left" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">Radiation Energy (keV)</th>
                                 <th styleCode="Rrule">Abundance (%)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Positron</td>
                                 <td styleCode="Rrule">249.8</td>
                                 <td styleCode="Rrule">96.9</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Gamma</td>
                                 <td styleCode="Rrule">511</td>
                                 <td styleCode="Rrule">193.5</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20230331"/>
                  </section>
               </component>
               <component>
                  <section ID="S11.3">
                     <id root="2f881a90-dffa-314d-e063-6294a90a6f9a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>11.3 External Radiation</title>
                     <text>
                        <paragraph>The point source air-kerma coefficient for F 18 is 3.75 × 10
 
  <sup>-17</sup>Gy m
 
  <sup>2</sup>/(Bq s). The first half-value thickness of lead (Pb) for F 18 gamma rays is approximately 6 mm. The relative reduction of radiation emitted by F 18 that results from various thicknesses of lead shielding is shown in Table 4. The use of 8 cm Pb decreases the radiation transmission (i.e. exposure) by a factor of about 10,000.

 </paragraph>
                        <table width="85%">
                           <caption>Table 4. Radiation Attenuation of 511 keV Gamma Rays by Lead Shielding</caption>
                           <col width="50%" align="center" valign="top"/>
                           <col width="50%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule">Shield Thickness cm of Lead (Pb)</th>
                                 <th styleCode="Rrule">Coefficient of Attenuation</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">0.6</td>
                                 <td styleCode="Rrule">0.5</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">2</td>
                                 <td styleCode="Rrule">0.1</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">4</td>
                                 <td styleCode="Rrule">0.01</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">6</td>
                                 <td styleCode="Rrule">0.001</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">8</td>
                                 <td styleCode="Rrule">0.0001</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20230331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="2f881a90-dffb-314d-e063-6294a90a6f9a"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20230331"/>
               <component>
                  <section ID="S12.1">
                     <id root="2f881a90-dffc-314d-e063-6294a90a6f9a"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Piflufolastat F 18 binds to cells that express PSMA, including malignant prostate cancer cells, which usually overexpress PSMA. Fluorine-18 (F 18) is a β+ emitting radionuclide that enables positron emission tomography.</paragraph>
                     </text>
                     <effectiveTime value="20230331"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="2f881a90-dffd-314d-e063-6294a90a6f9a"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>The relationship between piflufolastat F 18 plasma concentrations and image interpretation has not been studied.</paragraph>
                     </text>
                     <effectiveTime value="20230331"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="2f881a90-dffe-314d-e063-6294a90a6f9a"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <effectiveTime value="20230331"/>
                     <component>
                        <section>
                           <id root="2f881a90-dfff-314d-e063-6294a90a6f9a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>Following intravenous administration of piflufolastat F 18, blood levels decline in a biphasic fashion. The distribution half-life is 0.17 ± 0.044 hours and the elimination half-life is 3.47 ± 0.49 hours.</paragraph>
                              <paragraph>Piflufolastat F 18 distributes to the kidneys (16.5% of administered activity), liver (9.3%), and lung (2.9%), within 60 minutes of intravenous administration.</paragraph>
                           </text>
                           <effectiveTime value="20230331"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2f881a90-e000-314d-e063-6294a90a6f9a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>Elimination is by urinary excretion. In the first 8 hours post-injection, approximately 50% of administered radioactivity is excreted in the urine.</paragraph>
                           </text>
                           <effectiveTime value="20230331"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="2f881a90-e001-314d-e063-6294a90a6f9a"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20230331"/>
               <component>
                  <section ID="S13.1">
                     <id root="2f881a90-e002-314d-e063-6294a90a6f9a"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Animal studies to assess the carcinogenicity or mutagenic potential of piflufolastat have not been conducted. However, piflufolastat has the potential to be mutagenic because of the F 18 radioisotope.</paragraph>
                        <paragraph>No animal studies with piflufolastat have been performed to evaluate the potential impairment of fertility in males or females.</paragraph>
                     </text>
                     <effectiveTime value="20230331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="2f881a90-e003-314d-e063-6294a90a6f9a"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>The safety and efficacy of PYLARIFY were evaluated in two prospective, open-label, multi-center clinical studies in men with prostate cancer: OSPREY (NCT02981368) and CONDOR (NCT03739684).</paragraph>
               </text>
               <effectiveTime value="20230331"/>
               <component>
                  <section>
                     <id root="2f881a90-e004-314d-e063-6294a90a6f9a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">OSPREY</content>
                        </paragraph>
                        <paragraph>OSPREY enrolled a cohort of 268 men with biopsy-proven prostate cancer who were considered candidates for radical prostatectomy and pelvic lymph node dissection. These patients were all considered to have high risk disease based on criteria such as Gleason score, PSA level, and tumor stage. Each patient received a single PYLARIFY PET/CT from mid-thigh to skull vertex.</paragraph>
                        <paragraph>Three central readers independently interpreted each PET scan for the presence of abnormal PYLARIFY uptake in pelvic lymph nodes in multiple subregions, including the common iliac lymph nodes. The readers were blinded to all clinical information. While readers also recorded the presence of PYLARIFY PET-positive lesions in the prostate gland and outside the pelvis, those results were not included in the primary efficacy analysis.</paragraph>
                        <paragraph>A total of 252 patients (94%) underwent standard-of-care prostatectomy and template pelvic lymph node dissection and had sufficient histopathology data for evaluation of the pelvic lymph nodes. Surgical specimens were separated into three regions: left hemipelvis, right hemipelvis, and other. For each patient, PYLARIFY PET results and histopathology results obtained from dissected pelvic lymph nodes were compared by surgical region. PET results in locations that were not dissected were excluded from analysis.</paragraph>
                        <paragraph>For the 252 evaluable patients, the mean age was 64 years (range 46 to 84 years), and 87% were white. The median serum PSA was 9.3 ng/mL. The total Gleason score was 7 for 19%, 8 for 46%, and 9 for 34% of the patients, with the remainder of the patients having Gleason scores of 6 or 10.</paragraph>
                        <paragraph>Table 5 shows PYLARIFY PET performance by reader through comparison to pelvic lymph node histopathology at the patient-level with region matching, such that at least one true positive region defines a true positive patient. Approximately 24% of the evaluable patients had pelvic lymph node metastases based on histopathology (95% confidence interval: 19%, 29%).</paragraph>
                        <table width="85%">
                           <caption>Table 5: Patient-Level, Region-Matched Performance of PYLARIFY PET for Detection of Pelvic Lymph Node Metastasis in OSPREY (n=252)</caption>
                           <col width="25%" align="left" valign="top"/>
                           <col width="25%" align="center" valign="top"/>
                           <col width="25%" align="center" valign="top"/>
                           <col width="25%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">Reader 1</th>
                                 <th styleCode="Rrule">Reader 2</th>
                                 <th styleCode="Rrule">Reader 3</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="4" align="left">Abbreviations: CI = confidence interval, PPV = positive predictive value, NPV = negative predictive value</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">True Positive</td>
                                 <td styleCode="Rrule">23</td>
                                 <td styleCode="Rrule">17</td>
                                 <td styleCode="Rrule">23</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">False Positive</td>
                                 <td styleCode="Rrule">7</td>
                                 <td styleCode="Rrule">4</td>
                                 <td styleCode="Rrule">9</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">False Negative</td>
                                 <td styleCode="Rrule">36</td>
                                 <td styleCode="Rrule">43</td>
                                 <td styleCode="Rrule">37</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">True Negative</td>
                                 <td styleCode="Rrule">186</td>
                                 <td styleCode="Rrule">188</td>
                                 <td styleCode="Rrule">183</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Sensitivity, % (95% CI)</td>
                                 <td styleCode="Rrule">39 (27, 51)</td>
                                 <td styleCode="Rrule">28 (17, 40)</td>
                                 <td styleCode="Rrule">38 (26, 51)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Specificity, % (95% CI)</td>
                                 <td styleCode="Rrule">96 (94, 99)</td>
                                 <td styleCode="Rrule">98 (95, 99)</td>
                                 <td styleCode="Rrule">95 (92, 98)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">PPV, % (95% CI)</td>
                                 <td styleCode="Rrule">77 (62, 92)</td>
                                 <td styleCode="Rrule">81 (59, 93)</td>
                                 <td styleCode="Rrule">72 (56, 87)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">NPV, % (95% CI)</td>
                                 <td styleCode="Rrule">84 (79, 89)</td>
                                 <td styleCode="Rrule">81 (76, 86)</td>
                                 <td styleCode="Rrule">83 (78, 88)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In exploratory analyses, there were numerical trends towards more true positive results among patients with total Gleason score of 8 or higher and among patients with tumor stage of T2c or higher relative to those patients with lower Gleason score or tumor stage.</paragraph>
                     </text>
                     <effectiveTime value="20230331"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2f881a90-e005-314d-e063-6294a90a6f9a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">CONDOR</content>
                        </paragraph>
                        <paragraph>CONDOR enrolled 208 patients with biochemical evidence of recurrent prostate cancer, defined by serum PSA of at least 0.2 ng/mL after radical prostatectomy (with confirmatory PSA level also at least</paragraph>
                        <paragraph>0.2 ng/mL) or by an increase in serum PSA of at least 2 ng/mL above the nadir after other therapies. The mean age was 68 years (range 43 to 91 years), and 90% of patients were white. The median serum PSA was 0.82 ng/mL. Prior treatment included radical prostatectomy in 85% of the patients.</paragraph>
                        <paragraph>All enrolled patients had conventional imaging evaluation (for most patients, CT or MRI) within 60 days prior to receiving PYLARIFY PET, and this evaluation was negative or equivocal for prostate cancer. All patients received a single PYLARIFY PET/CT from mid-thigh to skull vertex with optional imaging of the lower extremities.</paragraph>
                        <paragraph>Three central readers independently evaluated each PYLARIFY PET scan for the presence and location of positive lesions. Location of each lesion was categorized in one of 19 subregions that were grouped into 5 regions (prostate/prostate bed, pelvic lymph nodes, other lymph nodes, soft tissue, bone). The readers were blinded to all clinical information.</paragraph>
                        <paragraph>Depending on the reader, a total of 123 to 137 patients (59% to 66%) had at least one lesion that was identified as PYLARIFY PET-positive (Table 6, TP + FP + PET-Positive Without Reference Standard). The region most commonly observed to have a PYLARIFY PET-positive finding was pelvic lymph nodes (40% to 42% of all PET-positive regions) and the least common region was soft tissue (6% to 7%).</paragraph>
                        <paragraph>Depending on the reader, 99 to 104 patients with a PYLARIFY PET-positive region had location-matched composite reference standard information available (Evaluable Set, Table 6, TP + FP) that consisted of histopathology, imaging (CT, MRI, ultrasound, fluciclovine PET, choline PET, or bone scan) obtained within 60 days of the PYLARIFY PET scan, or response of serum PSA level to targeted radiotherapy. Reference standard information for PET-negative regions was not systematically collected in this study.</paragraph>
                        <paragraph>Table 6 shows patient-level performance results of PYLARIFY PET by reader, including location -matched positive predictive value [true positive / (true positive + false positive)], also known as Correct Localization Rate (CLR). For these results, a patient was considered true positive if they had at least one matching location positive on both PYLARIFY PET and the composite reference standard. In addition to calculating location-matched positive predictive value in the Evaluable Set (CLR), an exploratory analysis of positive predictive value in all scanned patients (Imputed CLR) was performed in which PYLARIFY PET-positive patients who lacked reference standard information were imputed using an estimated likelihood that at least one PET-positive lesion was reference standard positive, based on patient-specific factors.</paragraph>
                        <table width="85%">
                           <caption>Table 6: Patient-Level Performance of PYLARIFY PET in CONDOR (n=208)</caption>
                           <col width="25%" align="left" valign="top"/>
                           <col width="25%" align="center" valign="top"/>
                           <col width="25%" align="center" valign="top"/>
                           <col width="25%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">Reader 1</th>
                                 <th styleCode="Rrule">Reader 2</th>
                                 <th styleCode="Rrule">Reader 3</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="4" align="left">Abbreviations: TP = true positive, FP = false positive, CLR = location-matched positive predictive value in the Evaluable Set [TP/(TP + FP)], Imputed CLR = location-matched positive predictive value in all scanned patients using an imputation approach based on patient-specific factors for PET-Positive Without Reference Standard, CI = confidence interval</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">True Positive (TP)</td>
                                 <td styleCode="Rrule">89</td>
                                 <td styleCode="Rrule">87</td>
                                 <td styleCode="Rrule">84</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">False Positive (FP)</td>
                                 <td styleCode="Rrule">15</td>
                                 <td styleCode="Rrule">13</td>
                                 <td styleCode="Rrule">15</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">PET-Positive Without Reference Standard</td>
                                 <td styleCode="Rrule">33</td>
                                 <td styleCode="Rrule">24</td>
                                 <td styleCode="Rrule">24</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">PET-Negative</td>
                                 <td styleCode="Rrule">71</td>
                                 <td styleCode="Rrule">84</td>
                                 <td styleCode="Rrule">85</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">CLR % (95% CI)</td>
                                 <td styleCode="Rrule">86 (79, 92)</td>
                                 <td styleCode="Rrule">87 (80, 94)</td>
                                 <td styleCode="Rrule">85 (78, 92)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Imputed CLR % (95% CI)</td>
                                 <td styleCode="Rrule">78 (71, 85)</td>
                                 <td styleCode="Rrule">81 (74, 88)</td>
                                 <td styleCode="Rrule">79 (72, 86)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>An exploratory analysis of region-level positive predictive value using only PET-positive regions that had sufficient composite reference standard information to determine true positive or false positive status demonstrated results of 67% to 70% with the lower bound of the 95% confidence interval ranging from 59% to 63%.</paragraph>
                        <paragraph>The percentage of patients categorized as true positive in a location-matched analysis out of all patients scanned with PYLARIFY was an additional exploratory endpoint. Using the same imputation approach for PET-positive patients who lacked reference standard information as in Table 6 above, this value was 47% to 51%, with the lower bound of the 95% confidence interval ranging from 40% to 45%.</paragraph>
                        <paragraph>Table 7 shows patient-level PYLARIFY PET results from the majority read stratified by serum PSA level. Percent PET positivity was calculated as the proportion of patients with a positive PYLARIFY PET out of all patients scanned. Percent PET positivity includes patients determined to be either true positive or false positive as well as those in whom such determination was not made due to lack of composite reference standard information. The likelihood of a patient having at least one PYLARIFY PET-positive lesion generally increased with higher serum PSA level.</paragraph>
                        <table width="85%">
                           <caption>Table 7: Patient-Level PYLARIFY PET Results and Percent PET Positivity
  
   <footnote ID="K3075">Percent PET positivity = PET positive patients/total patients scanned. PET positive patients include true positive and false positive patients as well as those who did not have reference standard information.</footnote>Stratified by Serum PSA Level in the CONDOR Study Using Majority Result Among Three Readers (n=199)
  
   <footnote ID="K3078">Six patients were excluded from this table due to lack of baseline PSA level. Three patients were excluded from this table due to lack of majority result among the categories true positive, false positive, PET positive without reference standard, and PET negative.</footnote>
                           </caption>
                           <col width="15%" align="left" valign="top"/>
                           <col width="14%" align="center" valign="top"/>
                           <col width="14%" align="center" valign="top"/>
                           <col width="14%" align="center" valign="top"/>
                           <col width="14%" align="center" valign="top"/>
                           <col width="14%" align="center" valign="top"/>
                           <col width="15%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th rowspan="3" styleCode="Lrule Rrule">PSA (ng/mL)</th>
                                 <th colspan="4" styleCode="Rrule Botrule">PET positive patients</th>
                                 <th rowspan="3" styleCode="Rrule">PET negative patients</th>
                                 <th rowspan="3" styleCode="Rrule">Percent PET positivity, (95% CI)</th>
                              </tr>
                              <tr styleCode="Botrule">
                                 <th rowspan="2" align="center" styleCode="Rrule">Total</th>
                                 <th styleCode="Rrule">TP</th>
                                 <th styleCode="Rrule">FP</th>
                                 <th align="center" rowspan="2" styleCode="Rrule">Without reference standard</th>
                              </tr>
                              <tr styleCode="Botrule">
                                 <th align="center" colspan="2" styleCode="Rrule">With reference standard</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="7" align="left">Abbreviations: TP = true positive, FP = false positive, CI = confidence interval</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td rowspan="2" styleCode="Lrule Rrule">&lt;0.5</td>
                                 <td rowspan="2" styleCode="Rrule">24</td>
                                 <td styleCode="Rrule">11</td>
                                 <td styleCode="Rrule">4</td>
                                 <td rowspan="2" styleCode="Rrule">9</td>
                                 <td rowspan="2" styleCode="Rrule">45</td>
                                 <td rowspan="2" styleCode="Rrule">35 (24, 46)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" colspan="2" styleCode="Rrule">15</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td rowspan="2" styleCode="Lrule Rrule">≥0.5 and &lt;1</td>
                                 <td rowspan="2" styleCode="Rrule">18</td>
                                 <td styleCode="Rrule">12</td>
                                 <td styleCode="Rrule">3</td>
                                 <td rowspan="2" styleCode="Rrule">3</td>
                                 <td rowspan="2" styleCode="Rrule">18</td>
                                 <td rowspan="2" styleCode="Rrule">50 (34, 66)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" colspan="2" styleCode="Rrule">15</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td rowspan="2" styleCode="Lrule Rrule">≥1 and &lt;2</td>
                                 <td rowspan="2" styleCode="Rrule">21</td>
                                 <td styleCode="Rrule">15</td>
                                 <td styleCode="Rrule">3</td>
                                 <td rowspan="2" styleCode="Rrule">3</td>
                                 <td rowspan="2" styleCode="Rrule">10</td>
                                 <td rowspan="2" styleCode="Rrule">68 (51, 84)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" colspan="2" styleCode="Rrule">18</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td rowspan="2" styleCode="Lrule Rrule">≥2</td>
                                 <td rowspan="2" styleCode="Rrule">57</td>
                                 <td styleCode="Rrule">50</td>
                                 <td styleCode="Rrule">3</td>
                                 <td rowspan="2" styleCode="Rrule">4</td>
                                 <td rowspan="2" styleCode="Rrule">6</td>
                                 <td rowspan="2" styleCode="Rrule">90 (83, 98)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" colspan="2" styleCode="Rrule">53</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td rowspan="2" styleCode="Lrule Rrule">Total</td>
                                 <td rowspan="2" styleCode="Rrule">120</td>
                                 <td styleCode="Rrule">88</td>
                                 <td styleCode="Rrule">13</td>
                                 <td rowspan="2" styleCode="Rrule">19</td>
                                 <td rowspan="2" styleCode="Rrule">79</td>
                                 <td rowspan="2" styleCode="Rrule">60 (54, 67)</td>
                              </tr>
                              <tr>
                                 <td align="center" colspan="2" styleCode="Rrule">101</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20230331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="2f881a90-e006-314d-e063-6294a90a6f9a"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20230331"/>
               <component>
                  <section ID="S16.1">
                     <id root="2f881a90-e007-314d-e063-6294a90a6f9a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>16.1 How Supplied</title>
                     <text>
                        <paragraph>PYLARIFY injection is supplied in a 50 mL multiple-dose glass vial (NDC# 71258-022-01) containing a clear, colorless solution at a strength of 37 MBq/mL to 2,960 MBq/mL (1 mCi/mL to 80 mCi/mL) piflufolastat F 18 at calibration time and date.</paragraph>
                     </text>
                     <effectiveTime value="20230331"/>
                  </section>
               </component>
               <component>
                  <section ID="S16.2">
                     <id root="2f881a90-e008-314d-e063-6294a90a6f9a"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>16.2 Storage and Handling</title>
                     <effectiveTime value="20230331"/>
                     <component>
                        <section>
                           <id root="2f881a90-e009-314d-e063-6294a90a6f9a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Storage</content>
                              </paragraph>
                              <paragraph>Store PYLARIFY at controlled room temperature (USP) 20°C to 25°C (68°F to 77°F). PYLARIFY does not contain a preservative. Store PYLARIFY in the original container with radiation shielding. The expiration date and time are provided on the container label. Use PYLARIFY within 10 hours from the time of end of synthesis.</paragraph>
                           </text>
                           <effectiveTime value="20230331"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2f881a90-e00a-314d-e063-6294a90a6f9a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Handling</content>
                              </paragraph>
                              <paragraph>This preparation is approved for use by persons under license by the Nuclear Regulatory Commission or the relevant regulatory authority of an Agreement State.</paragraph>
                           </text>
                           <effectiveTime value="20230331"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="2f881a90-e00b-314d-e063-6294a90a6f9a"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <effectiveTime value="20230331"/>
               <component>
                  <section>
                     <id root="2f881a90-e00c-314d-e063-6294a90a6f9a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Adequate Hydration</content>
                        </paragraph>
                        <paragraph>Instruct patients to drink a sufficient amount of water to ensure adequate hydration before their PET study and urge them to drink and urinate as often as possible during the first hours following the administration of PYLARIFY, in order to reduce radiation exposure [
 
  <content styleCode="italics">see
  
   <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>and
  
   <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>
                           </content>].

 </paragraph>
                     </text>
                     <effectiveTime value="20230331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="2f881a90-e00d-314d-e063-6294a90a6f9a"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Manufactured for: 
  <br/>  Progenics Pharmaceuticals, Inc., a Lantheus company 
  <br/>  331 Treble Cove Road 
  <br/>  N. Billerica, MA 01862
 </paragraph>
                  <paragraph>PYLARIFY
 
  <sup>®</sup>is a trademark of Progenics Pharmaceuticals, Inc.

 </paragraph>
                  <paragraph>Patent:
 
  <content styleCode="underline">http://www.lantheus.com/patents/index.html</content>
                  </paragraph>
                  <paragraph>516091-0323</paragraph>
               </text>
               <effectiveTime value="20230331"/>
            </section>
         </component>
         <component>
            <section>
               <id root="2f881a90-e00e-314d-e063-6294a90a6f9a"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 80 mCi/mL Vial Label</title>
               <text>
                  <paragraph>Sterile</paragraph>
                  <paragraph>PYLARIFY
 
  <sup>®</sup>
                     <br/>  (piflufolastat F 18) injection

 </paragraph>
                  <paragraph>Non-pyrogenic</paragraph>
                  <paragraph>37 MBq/mL to 2,960 MBq/mL (1 mCi/mL to 80 mCi/mL) 
  <br/>  at end of synthesis (EOS) 
  <br/>  Diagnostic – For Intravenous Use Only 
  <br/>  Expires within 10 hours from EOS
 </paragraph>
                  <paragraph>Batch #: _________</paragraph>
                  <paragraph>EOS Date:_________EOS Time: _________</paragraph>
                  <paragraph>Activity @ EOS:_________mCi</paragraph>
                  <paragraph>Concentration:_________mCi/mL</paragraph>
                  <paragraph>Volume:_________mL</paragraph>
                  <paragraph>Exp. Date:_________Exp. Time: _________</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20230331"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>PRINCIPAL DISPLAY PANEL - 80 mCi/mL Vial Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="pylarify-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>